Hamna Rafiq | Neuropharmacology | Best Researcher Award

Dr. Hamna Rafiq | Neuropharmacology | Best Researcher Award

Research Officer, Pakistan Council of Scientific and Industrial Research

Dr. Hamna Rafiq is a Research Officer at the Pharmaceutical Research Centre, Pakistan Council of Scientific & Industrial Research (PCSIR), Karachi. She holds a PhD in Biochemistry from the University of Karachi, focusing on neuroendocrine and behavioral abnormalities in oxidative stress models. Her expertise lies in neuropharmacology, pharmaceutical analysis, and cannabinoid research. She has contributed significantly to the development of cannabis-derived products, pharmaceutical raw material testing, and method validation per ICH and USP guidelines. Dr. Rafiq has extensive experience in HPLC, GC-MS, and ISO 17025 accreditation processes. Previously, she worked at Aga Khan University, researching natural antidepressants like chamomile and saffron. She has authored multiple high-impact research papers on neuropharmacology, cannabinoids, and neurodegenerative diseases. An active trainer, she has conducted hands-on workshops on advanced analytical techniques. Her research continues to explore therapeutic interventions for neuropathy, dementia, and neuroinflammation using pharmacological and computational approaches.

Profile

Scholar

🎓 Education 

Dr. Hamna Rafiq completed her PhD in Biochemistry from the University of Karachi (2015-2022). Her doctoral research explored the long-term effects of quercetin on behavioral and neuroendocrine abnormalities caused by oxidative stress in rats. She earned her MSc in Biochemistry (2012-2014) from the same institution, investigating the effects of a high-fat diet on stress response in a chronic mild stress rat model of depression. Throughout her academic journey, she gained expertise in pharmacological interventions, biochemical analysis, and neurobehavioral assessments. She has received extensive training in molecular techniques, protein purification, and tissue culture, enhancing her research capabilities. Additionally, she has attended specialized courses in analytical techniques such as HPLC and GC-MS. Dr. Rafiq’s educational background provides a strong foundation for her research in neuropharmacology, pharmaceutical development, and cannabinoid-based therapeutics, making significant contributions to biomedical sciences and drug discovery.

💼 Experience 

Dr. Hamna Rafiq has been a Research Officer at PCSIR, Karachi, since January 2022, where she specializes in cannabinoid extraction, pharmaceutical raw material testing, and method validation. She developed an animal model for chemotherapy-induced neuropathic pain to evaluate cannabinoid effects on dementia and psychological symptoms. She is proficient in HPLC, GC-MS, and ISO 17025 accreditation. From 2019 to 2021, she worked as a Research Associate at Aga Khan University, conducting clinical trials on chamomile and saffron for depression treatment. Her responsibilities included patient follow-ups, biochemical analyses, and documentation. Previously, she interned at PCSIR and ICCBS, gaining hands-on experience in quality control, analytical techniques, and neuronal cell culture. She also serves as a trainer for analytical instruments and has organized multiple workshops. Dr. Rafiq’s expertise spans neuropharmacology, drug discovery, and biomedical research, contributing to advancements in therapeutic interventions for neurological and psychological disorders.

🏆 Awards & Honors 

Dr. Hamna Rafiq has received multiple accolades for her contributions to neuropharmacology and pharmaceutical research. She has been recognized for her work in cannabis-derived therapeutics and neurodegenerative disease studies. In 2024, she received advanced training certifications in Lab Management Systems (LMS) and Internal Audits from the Pakistan National Accreditation Council. She has also been honored for organizing hands-on workshops on HPLC and GC-MS, training professionals and students in analytical methodologies. Her research publications in high-impact journals have earned significant recognition in the scientific community. She has contributed to ISO 17025 accreditation efforts for cannabinoid analysis, further strengthening laboratory quality assurance. Additionally, her pioneering research on saffron and chamomile as natural antidepressants has been widely acknowledged. With multiple peer-reviewed publications and active participation in international research collaborations, Dr. Rafiq continues to gain recognition as an emerging leader in neuropharmacology and biomedical sciences.

🔬 Research Focus 

Dr. Hamna Rafiq’s research focuses on neuropharmacology, cannabinoid therapeutics, and pharmaceutical analysis. She investigates the neuroprotective and anti-inflammatory properties of cannabis-derived compounds, particularly in treating neuropathy, dementia, and neurodegenerative disorders. Her work includes developing extraction methods for cannabinoids, optimizing analytical techniques for CBD and THC quantification, and ensuring compliance with pharmaceutical standards. She has also explored the effects of natural antidepressants like chamomile and saffron in clinical settings. Dr. Rafiq specializes in animal models for chemotherapy-induced pain and oxidative stress-related neurological disorders. Her expertise extends to method validation and impurity profiling in pharmaceutical raw materials, ensuring drug safety and efficacy. Through her computational studies, she identifies novel cannabinoid-based treatments targeting inflammatory pathways. Her interdisciplinary research integrates pharmacology, biochemistry, and analytical chemistry, contributing to drug discovery and therapeutic advancements in neuroscience and mental health.

Conclusion

Dr. Rafiq’s extensive research experience, publication record, and dedication to training make her a strong candidate for the Best Researcher Award. Addressing the identified areas for improvement could further bolster her candidacy and contribute to her professional growth.

Publication

M Farhan, H Rafi, H Rafiq (2018) – Behavioral evidence of neuropsychopharmacological effect of imipramine in animal model of unpredictable stress induced depression – 34 citations

 

H Rafi, H Rafiq, R Khan, F Ahmad, J Anis, M Farhan (2019) – Neuroethological study of ALCL3 and chronic forced swim stress induced memory and cognitive deficits in albino rats – 33 citations

 

H Rafiq, M Farhan, H Rafi, S Rehman, M Arshad, S Shakeel (2022) – Inhibition of drug induced Parkinsonism by chronic supplementation of quercetin in haloperidol-treated wistars – 32 citations

 

H Rafi, H Rafiq, M Farhan (2021) – Inhibition of NMDA receptors by agmatine is followed by GABA/glutamate balance in benzodiazepine withdrawal syndrome – 32 citations

 

H Rafi, H Rafiq, M Farhan (2024) – Pharmacological profile of agmatine: An in-depth overview – 30 citations

 

H Rafi, H Rafiq, M Farhan (2021) – Antagonization of monoamine reuptake transporters by agmatine improves anxiolytic and locomotive behaviors commensurate with fluoxetine and methylphenidate – 30 citations

 

M Farhan, H Rafi, H Rafiq (2015) – Dapoxetine treatment leads to attenuation of chronic unpredictable stress induced behavioral deficits in rats model of depression – 30 citations

 

H Rafi, F Ahmad, J Anis, R Khan, H Rafiq, M Farhan (2020) – Comparative effectiveness of agmatine and choline treatment in rats with cognitive impairment induced by AlCl3 and forced swim stress – 29 citations

 

M Farhan, H Rafiq, H Rafi, S Rehman, M Arshad (2022) – Quercetin impact against psychological disturbances induced by fat rich diet – 27 citations

 

M Farhan, H Rafiq, H Rafi, R Ali, S Jahan (2019) – Neuroprotective role of quercetin against neurotoxicity induced by lead acetate in male rats – 27 citations

 

H Rafi, H Rafiq, I Hanif, R Rizwan, M Farhan (2018) – Chronic agmatine treatment modulates behavioral deficits induced by chronic unpredictable stress in wistar rats – 27 citations

 

H Rafi, H Rafiq, M Farhan (2023) – Agmatine alleviates brain oxidative stress induced by sodium azide – 26 citations

 

M Farhan, H Rafi, H Rafiq, F Siddiqui, R Khan, J Anis (2019) – Study of mental illness in rat model of sodium azide induced oxidative stress – 24 citations

 

S Ahmad, SB Ahmed, A Khan, M Wasim, S Tabassum, S Haider, F Ahmed, … (2024) – Natural remedies for Alzheimer’s disease: A systematic review of randomized controlled trials – Metabolic brain disease 38 (1), 17-44

 

Syed Luqman Ali | Drug Design | Best Researcher Award

Mr. Syed Luqman Ali | Drug Design | Best Researcher Award

Researcher, Abdul Wali Khan University Mardan KPK Pakistan, Pakistan

Mr. Syed Luqman Ali is an enthusiastic researcher specializing in bioinformatics, computational biology, vaccine design, cancer, and drug development. Currently pursuing an MPhil in Biochemistry at Abdul Wali Khan University Mardan (2025), he has published extensively on vaccine and drug design using advanced computational techniques like RNA-seq, molecular docking, and simulation. Mr. Ali is a skilled reviewer for several high-impact journals and a lecturer at Metanoia College of Nursing. With expertise in bioinformatics tools and programming languages, he is committed to advancing scientific knowledge in vaccine and drug research.

Publication Profile

Google scholar

Education

Mr. Syed Luqman Ali is currently pursuing his MPhil in Biochemistry at Abdul Wali Khan University Mardan, Pakistan, with an expected graduation in 2025. He completed his Bachelor’s degree in Biochemistry from the same institution in 2022, laying the foundation for his research career. Additionally, he holds a Diploma in Digital Information Technology from the Board of Technical Education Peshawar, Pakistan, earned in 2021. This diverse educational background has equipped him with a strong interdisciplinary skill set, combining biochemistry, digital technology, and computational biology for cutting-edge research.

Research Experience

Mr. Syed Luqman Ali has been an Experimental and Computational Researcher at Abdul Wali Khan University Mardan since 2019. His research focuses on vaccine and drug design, utilizing advanced computational techniques like RNA-seq analysis, molecular docking, and simulation. With extensive experience in leading bioinformatics databases such as KEGG, MetaCyc, and HADDOCK, Mr. Ali is proficient in tools like SnapGene, Cytoscape, and DAVID. His work contributes to the development of innovative vaccines and drug therapies, advancing scientific knowledge in bioinformatics and computational biology.

Technical Certifications

Mr. Syed Luqman Ali has acquired several technical certifications that complement his research expertise. He completed a Data Analysis with R program through Mindluster, enhancing his data analysis skills. Additionally, he has obtained certifications in Data Analysis with Python and Linux from Udemy, further strengthening his computational abilities. Mr. Ali also completed a Content Writing course through the DigiSkills Training Program from Virtual University, Lahore, improving his communication and writing skills for scientific documentation. These certifications underscore his commitment to continuous learning and professional development in bioinformatics and computational biology.

Awards and Achievements

Mr. Syed Luqman Ali has made significant contributions to the scientific community, with multiple publications in high-impact journals, showcasing his research prowess in bioinformatics and computational biology. His work has been recognized by peers and researchers worldwide. Additionally, Mr. Ali serves as a reviewer for several reputed scientific journals, contributing his expertise to the advancement of research. These achievements reflect his dedication to scientific excellence and his active role in shaping future advancements in his field. 📚🖋️🔬

Research Focus

Mr. Syed Luqman Ali’s research spans multiple bioinformatics and computational biology domains, particularly in vaccine and drug design, cancer immunology, and genomics. His work includes multi-epitope vaccine development using immunoinformatics and reverse vaccinology approaches, along with genomic annotation for vaccine target identification. He has contributed significantly to disease diagnostics and drug discovery, especially in areas like tuberculosis, SARS-CoV-2, Leishmania, and autoimmune disorders. His expertise also extends to advanced data analysis, molecular docking, and RNA-seq analysis, employing tools like KEGG, MetaCyc, and HADDOCK. 🧬💻💉

Publication Top Notes

  • Mutational screening of GDAP1 in dysphonia associated with Charcot-Marie-Tooth disease: clinical insights and phenotypic effects
    Cited by: 20
    Year: 2023
  • Vaccinomics-based next-generation multi-epitope chimeric vaccine models prediction against Leishmania tropica – a hierarchical subtractive proteomics and …
    Cited by: 15
    Year: 2023
  • Genomic annotation for vaccine target identification and immunoinformatics-guided multi-epitope-based vaccine design against Songling virus through screening its whole genome …
    Cited by: 12
    Year: 2023
  • Currently trending and futuristic biological modalities in the management of different types of diabetes: A comprehensive review
    Cited by: 9
    Year: 2023
  • Analysis of the capability of IgG antibodies and receptors with their relationships to food tolerance and autoimmune disorders
    Cited by: 6
    Year: 2023
  • Illuminating the Frontier of Drug Discovery: Unleashing the Power of Bioinformatics for Unprecedented Breakthroughs
    Cited by: 4
    Year: 2023
  • Leveraging computer-aided design and artificial intelligence to develop a next-generation multi-epitope tuberculosis vaccine candidate
    Cited by: 1
    Year: 2024
  • Genetic identification and determination of parasites (Babesia, Leptospira and Toxoplasma Gondi) in wild rats
    Cited by: 1
    Year: 2024
  • Placental histology for targeted risk assessment of recurrent spontaneous preterm birth
    Cited by: 1
    Year: 2024
  • Harnessing bioinformatics for the development of a promising multi-epitope vaccine against tuberculosis: The ZL9810L vaccine
    Cited by: 1
    Year: 2024
  • Promising vaccine models against astrovirus MLB2 using integrated vaccinomics and immunoinformatics approaches
    Cited by: 1
    Year: 2024
  • Multi-epitope-based vaccine models prioritization against Astrovirus MLB1 using immunoinformatics and reverse vaccinology approaches
    Cited by: 1
    Year: 2025
  • Exploring advanced genomic and immunoinformatics techniques for identifying drug and vaccine targets against SARS-CoV-2
    Cited by: 1
    Year: 2024
  • A Comprehensive Methodological Review of Major Developments in Bioinformatics Pipelines for Transcriptomic Data Analysis
    Cited by: –
    Year: 2024
Conclusion

Mr. Ali’s solid academic background, innovative research contributions, advanced technical skills, and role as a mentor, he is undoubtedly a strong candidate for the Research for Best Researcher Award. His work in bioinformatics, drug design, vaccine development, and cancer research showcases his dedication to advancing scientific knowledge and making a global impact.